Egypt - English - EDA (Egyptian Drug Authority)

novartis pharma egypt - suppository - 300 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ondansetron, quantity: 16 mg - suppository, moulded - excipient ingredients: hard fat; cetomacrogol 1000; glyceryl ricinoleate - ondansetron (tablets, syrup, injection and suppository) is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron (injection) is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - diclofenac sodium - suppository - 12.5 mg - diclofenac sodium 12.5 mg

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - diclofenac sodium - suppository - 25 mg - diclofenac sodium 25 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

adcock ingram limited - suppository - see ingredients - each suppository contains cinchocaine hydrochloride 1,0 mg prednisolone hexanoate 1,3 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48321 - hepatitis b virus surface antigen ivd, kit, chemiluminescent immunoassay - liaison? xl murex hbsag quant assay uses chemiluminescence immunoassay (clia) technology for the quantitative determination of hepatitis b surface antigen (hbsag) in human serum or plasma samples. for the quantitative determination of hepatitis b surface antigen (hbsag) in human serum and plasma samples, including specimens collected up to 24 hours post-mortem (non-heart beating).

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48366 - hepatitis c virus total antibody ivd, kit, chemiluminescent assay - the liaison? xl murex hcv ab assay uses chemiluminescence immunoassay (clia) technology for the qualitative determination of specific antibodies to hepatitis c virus (anti-hcv) in human serum or plasma samples. the test has to be performed on the liaison? xl analyzers only. for the qualitative determination of specific antibodies to hepatitis c virus (anti-hcv) in human serum or plasma samples. post mortem samples collected up to 24 hours after death have been tested and may be also used in the assay.

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48446 - hiv1/hiv2 antigen/antibody ivd, kit, chemiluminescent immunoassay - the liaison? xl murex hiv ab / ag assay uses chemiluminescence immunoassay (clia) technology for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (hiv-1) and specific antibodies to both human immunodeficiency virus type 1 (group m and group o) and/or human immunodeficiency virus type 2 (hiv-2) in human serum or plasma samples for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (hiv-1) and specific antibodies to both human immunodeficiency virus type 1 (group m and group o) and/or human immunodeficiency virus type 2 (hiv-2) in human serum or plasma samples. post mortem samples collected up to 24 hours after death have been tested and may be also used in the assay.

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48446 - hiv1/hiv2 antigen/antibody ivd, kit, chemiluminescent immunoassay - the liaison? xl murex hiv ab / ag ht assay uses chemiluminescence immunoassay (clia) technology for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (hiv-1) and specific antibodies to both human immunodeficiency virus type 1 (group m and group o) and/or human immunodeficiency virus type 2 (hiv-2) in human serum or plasma samples. ivds that are intended to be used in testing to provide information about infection with or exposure to human immunodeficiency viruses (hiv)

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48524 - human t-cell lymphotrophic virus 1 & 2 (htlv1 & htlv2) antibody ivd, kit, chemiluminescent immunoassay - the liaison? xl murex rechtlv-i/ii assay uses chemiluminescence immunoassay (clia) technology for the qualitative determination of specific antibodies to human t-cell lymphotropic virus (htlv) type i and type ii (anti-htlv-i and anti-htlv-ii) in human serum or plasma samples. for the qualitative determination of antibodies to human t-cell lymphotropic virus type 1 and/or type ii (htlv-i/ii) in human serum and plasma, including specimens collected up to 24 hours post mortem (non-heart beating).